SG Americas Securities LLC Sells 260,544 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

SG Americas Securities LLC lowered its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 98.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,081 shares of the company’s stock after selling 260,544 shares during the quarter. SG Americas Securities LLC’s holdings in Centessa Pharmaceuticals were worth $122,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in CNTA. TD Waterhouse Canada Inc. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth about $36,000. T. Rowe Price Investment Management Inc. grew its holdings in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares during the last quarter. Wells Fargo & Company MN increased its position in Centessa Pharmaceuticals by 42.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr acquired a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $100,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $40.50 on Tuesday. The stock has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 1-year low of $12.74 and a 1-year high of $40.56. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The business has a 50-day moving average price of $39.98 and a two-hundred day moving average price of $32.77.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on CNTA. Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their target price for the stock from $36.00 to $40.00 in a research report on Wednesday, April 1st. B. Riley Financial lowered shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 31st. Lifesci Capital cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Finally, Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.